ニュース

最新ニュース

東京証券取引所グロース市場への上場承認に関するお知らせ

Presentation of the main results of the phase 2/3 ACTISAVE study in the treatment of stroke at ESOC 2024

Acticor Biotech will present the clinical results of its phase 2/3 ACTISAVE study in the treatment of stroke at ESOC 2024

SEQUANA MEDICAL SUCCESSFULLY RAISES EUR 11.5 MILLION IN AN EQUITY PLACEMENT

Acticor Biotech completes a capital increase for a total gross amount of 8 million euros

Sequana Medical announces DSMB approval to start randomized MOJAVE cohort – US Phase 1/2a study of DSR® 2.0 for treatment of heart failure

PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions

Sequana Medical granted US CPT® III reimbursement codes for alfapump® system

30th 11月 2023

Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure

1
2
3